RGLS - Regulus Therapeutics Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Regulus Therapeutics Inc.

10614 Science Center Drive
San Diego, CA 92121
United States
858-202-6300
http://www.regulusrx.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees21

Key Executives

NameTitlePayExercisedYear Born
Mr. Joseph P. Hagan M.B.A.Pres, CEO, Interim CFO & Director758.25kN/A1969
Mr. Daniel R. ChevallardExec. Officer448.33kN/A1980
Mr. Daniel PenksaController & Principal Accounting OfficerN/AN/A1985
Mr. Christopher Ray Aker J.D.Sr. VP. Gen. Counsel & Corp. Sec.N/AN/A1961
Mr. Turner JenkinsSr. Director of Corp. Devel.N/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products, which include RGLS5579 to inhibit miR-10b, and Hepatitis B virus program and Non-Alcoholic Steatohepatitis program. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.

Corporate Governance

Regulus Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.